Profound Medical names Richard Fabian as president

Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) has appointed Richard Fabian as president, effective immediately, according to a press release from the Toronto-based medical device company.

Fabian succeeds Mathieu Burtnyk, PhD, who moves to a newly created role of Chief Technology Officer. Burtnyk is credited as the inventor of the patented closed-loop temperature feedback control algorithm used in the company's TULSA-PRO device and has led clinical studies for the technology, including the ongoing CAPTAIN randomized controlled trial.

Fabian brings more than 29 years of experience in the healthcare industry, with a background in medical imaging and medical devices. He most recently served as Chief Executive Officer of Fujifilm Sonosite, Inc., a point-of-care ultrasound company. Before that role, which began in 2017, he held multiple executive positions at Philips Healthcare, a division of NYSE and AEX-listed Royal Philips, starting in 2002 as Senior Director in the Cardiovascular X-ray Business Unit in North America. Earlier in his career, he served as VP of Sales at Noetix Corporation and VP of Operations at Steris Corporation.

Fabian holds a Bachelor of Economics degree from the University of Michigan and a Master of Business Administration from the University of Pittsburgh Joseph M. Katz Graduate School of Business.

"Rich is a seasoned leader with a strong track record of delivering profitable growth to both established and emerging healthcare businesses," said Arun Menawat, Profound's CEO and Chairman.

Profound Medical develops and markets interventional MRI procedures, including its TULSA-PRO platform for MRI-guided prostate tissue ablation and Sonalleve, used for non-surgical treatment of conditions including bone metastases pain and uterine fibroids.

You May Also Be Interested In

• Polaryx Therapeutics names Will Charlton as chief medical officer
• Metallus CEO Michael Williams to retire; Kris Westbrooks named successor
• BlossomHill to present BH-30643 trial data at lung cancer conference